

PUBBLICAZIONI su RIVISTE SCIENTIFICHE

Perotti V, Baldassari P, Molla A, Nicolini G, Bersani I, Grazia G, Benigni F, **Maurichi A**, Santinami M, Anichini A, Mortarini R. An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells. *Oncogene*. 2019 Feb 1. doi: 10.1038/s41388-019-0729-2

Perotti V, Baldassari P, Molla A, Vegetti C, Bersani I, **Maurichi A**, Santinami M, Anichini A, Mortarini R. Correction to: NFATc2 is an intrinsic regulator of melanoma dedifferentiation. *Oncogene*. 2019 Jan 28. doi: 10.1038/s41388-019-0679-8.

Femia D, Prinzi N, Anichini A, Mortarini R, Nichetti F, Corti F, Torchio M, Peverelli G, Pagani F, **Maurichi A**, Mattavelli I, Milione M, Bedini N, Corti A, Di Bartolomeo M, de Braud F, Pusceddu S. Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. *Target Oncol*. 2018 Oct;13(5):567-582.

Cavaliere S, Perrone F, Miceli R, Ascierio PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, **Maurichi A**, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. *Eur J Cancer*. 2018 Jul;97:7-15.

Brecht IB, De Paoli A, Bisogno G, Orbach D, Schneider DT, Leiter U, Offenmueller S, Cecchetto G, Godzinski J, Bien E, Stachowicz-Stencel T, Ben-Ami T, Chiaravalli S, **Maurichi A**, De Salvo GL, Sorbara S, Bodemer C, Garbe C, Reguerre Y, Ferrari A. Pediatric patients with cutaneous melanoma: A European study. *Pediatr Blood Cancer*. 2018 Jun;65(6):e26974

Zugna D, Senetta R, Osella-Abate S, Fierro MT, Pisacane A, Zaccagna A, Sapino A, Bataille V, **Maurichi A**, Picciotto F, Cassoni P, Quaglino P, Ribero S. Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients. *Br J Cancer*. 2018 Feb 6;118(3):398-404

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.

Collaborators (48): Gershenwald JE, Scolyer RA, Atkins MB, Balch CM, Barnhill RL, Bilimoria KY, Buzaid AC, Byrd DR, Cochran AJ, Eggermont AMM, Elder DE, Faries MB, Flaherty KT, Garbe C, Gardner JM, Gimotty PA, Halpern AC, Haydu LE, Hess KR, Johnson TM, Kirkwood JM, Lazar AJ, Lee AWM, Long GV, McArthur GA, Mihm MC Jr, Prieto VG, Ross MI, Sober AJ, Sondak VK, Thompson JF, Wong SL, Delman KA, Santinami M, **Maurichi A**, Nagore E, Faries MB, Thompson JF, Scolyer RA, McArthur GA, Gyorki DE, Henderson M, Stratigos AJ, Gogas H, Gershenwald JE, Haydu LE, Rossi CR, Sommariva A. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin*. 2017 Nov;67(6):472-492

Calvi A, De Riz M, Lecchi E, Pietrobboni A, Ghezzi L, Scarioni M, Carandini T, Pellegrielli A, **Maurichi A**, Galimberti D, Scarpini E. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod. *J Neurol Sci*. 2017 Oct 15;381:296-297

Sangalli A, Orlandi E, Poli A, **Maurichi A**, Santinami M, Nicolis M, Ferronato S, Malerba G, Rodolfo M, Gomez Lira M. Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer. *Melanoma Res*. 2017 Aug;27(4):309-314.

Mattavelli I, Patuzzo R, Torri V, Gallino G, **Maurichi A**, Lamera M, Valeri B, Bolzonaro E, Barbieri C, Tolomio E, Moglia D, Nespoli AM, Galeone C, Saw R, Santinami M. Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy. *Eur J Surg Oncol*. 2017 Aug;43(8):1536-1541.

Vallacchi V, Camisaschi C, Dugo M, Vergani E, Deho P, Gualeni A, Huber V, Gloghini A, **Maurichi A**, Santinami M, Sensi M, Castelli C, Rivoltini L, Rodolfo M. microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response. *Genes (Basel)*. 2016 Dec 14;7(12).

Kohli JS, Tolomio E, Frigerio S, **Maurichi A**, Rodolfo M, Bennett DC. Common Delayed Senescence of Melanocytes from Multiple Primary Melanoma Patients. *J Invest Dermatol*. 2017 Mar;137(3):766-768.

Bruno W, Pastorino L, Ghiorzo P, Andreotti V, Martinuzzi C, Menin C, Elefanti L, Stagni C, Vecchiato A, Rodolfo M, **Maurichi A**, Manoukian S, De Giorgi V, Savarese I, Gensini F, Borgognoni L, Testori A, Spadola G, Mandalà M, Imberti G, Savoia P, Astrua C, Ronco AM, Farnetti A, Tibiletti MG, Lombardo M, Palmieri G, Ayala F, Ascierto P, Ghigliotti G, Muggianu M, Spagnolo F, Picasso V, Tanda ET, Queirolo P, Bianchi-Scarrà G. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. *J Am Acad Dermatol*. 2016 Feb;74(2):325-32.

Perotti V, Baldassari P, Molla A, Vegetti C, Bersani I, **Maurichi A**, Santinami M, Anichini A, Mortarini R. NFATc2 is an intrinsic regulator of melanoma dedifferentiation. *Oncogene*. 2016 Jun 2;35(22):2862-72.

Danielli R, Patuzzo R, Di Giacomo AM, Gallino G, **Maurichi A**, Di Florio A, Cutaia O, Lazzeri A, Fazio C, Miracco C, Giovannoni L, Elia G, Neri D, Maio M, Santinami M. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. *Cancer Immunol Immunother*. 2015 Aug;64(8):999-1009.

Fava P, Astrua C, Chiarugi A, Crocetti E, Pimpinelli N, Fagnoli MC, **Maurichi A**, Rubegni P, Manganoni AM, Bottoni U, Catricalà C, Cavicchini S, Santinami M, Alaibac M, Annetta A, Borghi A, Calzavara Pinton P, Capizzi R, Clerico R, Colombo E, Corradin MT, De Simone P, Fantini F, Ferrel C, Filosa G, Girgenti V, Giulioni E, Guarneri C, Lamberti A, Lisi P, Nardini P, Papini M, Peris K, Pizzichetta MA, Salvini C, Savoia P, Strippoli D, Tolomio E, Tomassini MA, Vena GA, Zichichi L, Patrizi A, Argenziano G, Simonacci M, Quaglino P. Differences in clinicopathological features and distribution of risk factors in Italian melanoma patients. *Dermatology*. 2015;230(3):256-62.

Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, **Maurichi A**, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. *Ann Oncol*. 2015 Apr;26(4):798-803.

Danielli R, Patuzzo R, Ruffini PA, **Maurichi A**, Giovannoni L, Elia G, Neri D, Santinami M. Armed antibodies for cancer treatment: a promising tool in a changing era. *Cancer Immunol Immunother*. 2015 Jan;64(1):113-21.

Gomez-Lira M, Ferronato S, Malerba G, Santinami M, **Maurichi A**, Sangalli A, Turco A, Perego P, Rodolfo M. Association of promoter polymorphism -765G>C in the PTGS2 gene with malignant melanoma in Italian patients and its correlation to gene expression in dermal fibroblasts. *Exp Dermatol*. 2014;23:766-768

Maurichi A, Miceli R, Camerini T, Mariani L, Patuzzo R, Ruggeri R, Gallino G, Tolomio E, Tragni G, Valeri B, Anichini A, Mortarini R, Moglia D, Pellacani G, Bassoli S, Longo C, Quaglino P, Pimpinelli N, Borgognoni L, Bergamaschi D, Harwood C, Zoras O, Santinami M. Prediction of survival in patients with thin melanoma: results from a multi-institution study. *J Clin Oncol*. 2014;32:2479-2485

Frigerio S, Disciglio V, Manoukian S, Peissel B, Della Torre G, **Maurichi A**, Collini P, Pasini B, Gotti G, Ferrari A, Rivoltini L, Massimino M, Rodolfo M. A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma. *BMC Med Genet*. 2014;15:59

Rossi CR, Mozzillo N, **Maurichi A**, Pasquali S, Macripò G, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Mocellin S, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M. Number of excised lymph nodes as a quality assurance measure for lymphadenectomy in melanoma. *JAMA Surg*. 2014;149:700-706

Pasquali S, Mocellin S, Mozzillo N, **Maurichi A**, Quaglinò P, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M, Rossi CR. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. *J Clin Oncol*. 2014;32:935-941

Rossi CR, Mozzillo N, **Maurichi A**, Pasquali S, Quaglinò P, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Mocellin S, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M. The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis. *Ann Oncol*. 2014;25:240-246.

Patuzzo R, **Maurichi A**, Camerini T, Gallino G, Ruggeri R, Baffa G, Mattavelli I, Tinti MC, Crippa F, Moglia D, Tolomio E, Maccauro M, Santinami M. [Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas](#). *J Surg Res*. 2014;187:518-524.

Ferrari A, Bisogno G, Cecchetto G, Santinami M, **Maurichi A**, Bono A, Vajna De Pava M, Pierani P, Bertolini P, Rossi CR, De Salvo GL. [Cutaneous Melanoma in Children and Adolescents: The Italian Rare Tumors in Pediatric Age Project Experience](#). *J Pediatr*. 2014;164:376-382.e1-2

Pollio A, Tomasi A, Seidenari S, Pellacani G, Rodolfo M, Frigerio S, **Maurichi A**, Turchetti D, Bassoli S, Ruini C, Ponti G.
Malignant and benign tumors associated with multiple primary melanomas: just the starting block for the involvement of MITF, PTEN and CDKN2A in multiple cancerogenesis? *Pigment Cell Melanoma Res*. 2013;26:755-7

Bassoli S, **Maurichi A**, Rodolfo M, Casari A, Frigerio S, Pupelli G, Farnetani F, Pelosi G, Santinami M, Pellacani G. CDKN2A and MC1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients. *Exp Dermatol*. 2013 Jun;22(6):411-6. doi: 10.1111/exd.12168.

Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, **Maurichi A**, Cova A, Maio M, Chiarion-Sileni V, Tragni G, Santinami M, Vergani B, Villa A, Berti E, Umansky L, Beckhove P, Umansky V, Parmiani G, Rivoltini L, Castelli C. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. *Cancer Immunol Immunother*. 2013 May;62(5):897-908. doi: 10.1007/s00262-013-1397-7. Epub 2013 Apr 16.

Ruggeri R, Camerini T, Patuzzo R, **Maurichi A**, Pirovano R, Mattavelli I, Crippa F, Tolomio E, Moglia D, Di Florio A, Santinami M. The use of polytetrafluoroethylene to facilitate the vascular access in recurrent melanoma to limbs. *Int J Surg Case Rep*. 2013;4(1):40-3. doi: 10.1016/j.ijscr.2012.08.013. Epub 2012 Sep 27.

Bossi P, Resteghini C, Perrone F, Cortelazzi B, Pilotti S, **Maurichi A**, Locati LD, Licitra L. Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. *J Am Acad Dermatol*. 2012 Nov;67(5):e226-8. doi: 10.1016/j.jaad.2012.04.029. No abstract available.

Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, **Maurichi A**, Cova A, Rigamonti G, Giardino F, Di Florio A, Asioli M, Frati P, Sovena G, Squarcina P, Maio M, Danielli R, Chiarion-Sileni V, Villa A, Lombardo C, Tragni G, Santinami M, Parmiani G, Rivoltini L.

Limited Induction of Tumor-cross-reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen-Class I-Modified Peptides. *Clin Cancer Res.* 2012 Oct 2.

Papadia F, Basso V, Patuzzo R, **Maurichi A**, Di Florio A, Zardi L, Ventura E, González-Iglesias R, Lovato V, Giovannoni L, Tasciotti A, Neri D, Santinami M, Menssen HD, De Cian F. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. *J Surg Oncol.* 2012 Jun 4

Chiarugi A, Nardini P, Crocetti E, Carli P, De Giorgi V, Borgognoni L, Brandani P, Pimpinelli N, Manganoni AM, Quaglino P; GIPMe Participants Centres. Familial and sporadic melanoma: different clinical and histopathological features in the Italian population - a multicentre epidemiological study - by GIPMe (Italian Multidisciplinary Group on Melanoma). *J Eur Acad Dermatol Venereol.* 2012 Feb;26(2):194-9.

Maurichi A, Miceli R, Camerini T, Contiero P, Patuzzo R, Tragni G, Crippa F, Romanidis K, Ruggeri R, Carbone A, Santinami M. Pure desmoplastic melanoma: a melanoma with distinctive clinical behavior. *Ann Surg.* 2010 Dec;252(6):1052-7.

Anichini A, Molla A, Vegetti C, Bersani I, Zappasodi R, Arienti F, Ravagnani F, **Maurichi A**, Patuzzo R, Santinami M, Pircher H, Di Nicola M, Mortarini R. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma. *Cancer Res.* 2010 Nov 1;70(21):8378-87.

Bajetta E, Celio L, Platania M, Lo Vullo S, Patuzzo R, **Maurichi A**, Santinami M. Single-institution series of early-stage Merkel cell carcinoma: long-term outcomes in 95 patients managed with surgery alone. *Ann Surg Oncol.* 2009 Nov;16(11):2985-93.

Stacey SN, Sulem P, Masson G, Gudjonsson SA, Thorleifsson G, Jakobsdottir M, Sigurdsson A, Gudbjartsson DF, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Scherer D, Hemminki K, Rudnai P, Gurzau E, Koppova K, Botella-Estrada R, Soriano V, Juberias P, Saez B, Gilaberte Y, Fuentelsaz V, Corredera C, Grasa M, Höiom V, Lindblom A, Bonenkamp JJ, van Rossum MM, Aben KK, de Vries E, Santinami M, Di Mauro MG, **Maurichi A**, Wendt J, Hochleitner P, Pehamberger H, Gudmundsson J, Magnúsdóttir DN, Gretarsdóttir S, Holm H, Steinhorsdóttir V, Frigge ML, Blondal T, Saemundsdóttir J, Bjarnason H, Kristjánsson K, Bjornsdóttir G, Okamoto I, Rivoltini L, Rodolfo M, Kiemeny LA, Hansson J, Nagore E, Mayordomo JI, Kumar R, Karagas MR, Nelson HH, Gulcher JR, Rafnar T, Thorsteinsdóttir U, Olafsson JH, Kong A, Stefansson K. New common variants affecting susceptibility to basal cell carcinoma. *Nat Genet.* 2009 Aug;41(8):909-14.

Mortarini R, Vegetti C, Molla A, Arienti F, Ravagnani F, **Maurichi A**, Patuzzo R, Santinami M, Anichini A. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. *Clin Cancer Res.* 2009 Jun 15;15(12):4085-94.

Santinami M, Carbone A, Crippa F, **Maurichi A**, Pellitteri C, Ruggeri R, Zoras O, Patuzzo R. Radical dissection after positive groin sentinel biopsy in melanoma patients: rate of further positive nodes. *Melanoma Res.* 2009 Apr;19(2):112-8.

Cascinelli N, Bombardieri E, Bufalino R, Camerini T, Carbone A, Clemente C, Lenisa L, Mascheroni L, Maurichi A, Pennacchioli E, Patuzzo R, Santinami M, Tragni G. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. *J Clin Oncol.* 2006 Sep 20;24(27):4464-71.

Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, **Maurichi A**, Massarut S, Marchiano A, Santantonio C, Tosi D, Arienti F, Cova A, Sovena G, Piris A, Nonaka D, Bersani I, Florio AD, Luigi M, Srivastava PK, Hoos A, Santinami M, Parmiani G. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. *Cancer Immunol Immunother.* 2006 Aug;55(8):958-68.

Carli P, De Giorgi V, Palli D, **Maurichi A**, Mulas P, Orlandi C, Imberti G, Stanganelli I, Soma P, Dioguardi D, Catricala C, Betti R, Paoli S, Bottoni U, Lo Scocco G, Scalvenzi M, Giannotti B. Self-detected cutaneous melanomas in Italian patients. *Clin Exp Dermatol*. 2004 Nov;29(6):593-6.

Maurichi A, Baldi M, Bartoli C, Bono A, Camerini T, Moglia D, Patuzzo R, Pennacchioli E, Tragni G, Santinami M. Pigmented spindle - cell nevus: a melanoma simulator. *Dermatol Online J*. 2004 Oct 15;10(2):5.

Carli P, De Giorgi V, Palli D, **Maurichi A**, Mulas P, Orlandi C, Imberti G, Stanganelli I, Soma P, Dioguardi D, Catricala C, Betti R, Paoli S, Bottoni U, Lo Scocco G, Scalvenzi M, Giannotti B. Patterns of detection of superficial spreading and nodular-type melanoma: a multicenter Italian study. *Dermatol Surg*. 2004 Nov;30(11):1371-5; discussion 1375-6.

Santinami M, Baldi M, Tragni G, **Maurichi A**, Moglia D, Bono A, Bartoli C, Patuzzo R, Pennacchioli E, Cascinelli N. Impact of sentinel lymph node biopsy on the treatment of melanoma. *Tumori*. 2003 Jul-Aug;89(4 Suppl):273-5.

Carli P, De Giorgi V, Palli D, **Maurichi A**, Mulas P, Orlandi C, Imberti GL, Stanganelli I, Soma P, Dioguardi D, Catricala C, Betti R, Cecchi R, Bottoni U, Bonci A, Scalvenzi M, Giannotti B; Italian Multidisciplinary Group on Melanoma. Dermatologist detection and skin self - examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. *Arch Dermatol*. 2003 May;139(5):607-12.

Mortarini R, Piris A, **Maurichi A**, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. *Cancer Res*. 2003 May 15;63(10):2535-45.

Cascinelli N, Santinami M, **Maurichi A**, Patuzzo R, Pennacchioli E. World Health Organization experience in the treatment of melanoma. *Surg Clin North Am*. 2003 Apr; 83(2):405-16.

Bono A, Baldi M, **Maurichi A**, Tomatis S. Distribution of melanoma on breast surface suggests its etiology. *Int J Cancer*. 2003 Jun 20;105(3):434.

Gariboldi M, Peissel B, Fabbri A, Saran A, Zaffaroni D, Falvella FS, Spinola M, Tanuma J, Pazzaglia S, Mancuso MT, **Maurichi A**, Bartoli C, Cataltepe S, Silverman GA, Pilotti S, Hayashizaki Y, Okazaki Y, Dragani TA. SCCA2-like serpins mediate genetic predisposition to skin tumors. *Cancer Res*. 2003 Apr 15;63(8):1871-5.

Bono A, Bartoli C, Cascinelli N, Lualdi M, **Maurichi A**, Moglia D, Tragni G, Tomatis S, Marchesini R. Melanoma detection. A prospective study comparing diagnosis with the naked eye, dermatoscopy and telespectrophotometry. *Dermatology*. 2002;205(4):362-6.

Santinami M, **Maurichi A**, Patuzzo R, Pennacchioli E, Cascinelli N. Impact of clinical trials on the treatment of melanoma. *Surg Oncol Clin N Am*. 2001 Oct;10(4):935-47.

Bono A, **Maurichi A**, Moglia D, Camerini T, Tragni G, Lualdi M, Bartoli C. Clinical and dermatoscopic diagnosis of early amelanotic melanoma. *Melanoma Res*. 2001 Oct;11(5):491-4.

Bono A, Bartoli C, Moglia D, **Maurichi A**, Camerini T, Grassi G, Tragni G, Cascinelli N. Small melanomas: how many are they? A clinical study on 270 consecutive cases of cutaneous melanoma. *Melanoma Res*. 1999 Dec;9(6):583-6.

Bono A, Tomatis S, Bartoli C, Tragni G, Radaelli G, **Maurichi A**, Marchesini R. The ABCD system of melanoma detection: a spectrophotometric analysis of the Asymmetry, Border, Color, and Dimension. *Cancer*. 1999 Jan 1;85(1):72-7.

Bono A, Bartoli C, **Maurichi A**, Moglia D, Tragni G. Melanoma of the external ear. *Tumori*. 1997

Sep-Oct;83(5):814-7.

COMUNICAZIONI su RIVISTE SCIENTIFICHE

Platania S, Bajetta E, Catena L, Colombo A, Ducceschi M, Pusceddu S, Procopio G, Buzzoni R, Di Bartolomeo M, Guadalupi V, Pietrantonio F, Patuzzo R, **Maurichi A**, Crippa F, Santinami M. Merkel Cell Carcinoma: a Large Series from a Single Institution. *Annals of Oncology*, Vol 19, Suppl 9, G19 October 2008.

Cascinelli N, Baldi M, Bartoli C, Bono A, **Maurichi A**, Moglia D, Patuzzo R, Pennacchioli E, Santinami M. Extent of lymphadenectomy. *European Journal of Surgical Oncology*, Vol. 28, Number 3, S276; April 2002.

Bono A, **Maurichi A**, Moglia D, Tragni G, Camerini T, Bartoli C. Clinical diagnosis of amelanotic melanoma. *Melanoma Research*, Vol.11, Suppl 1, S122; February 2001.

Bono A, Bartoli C, Moglia D, **Maurichi A**, Camerini T. Ambulatory surgery for cutaneous melanoma. *Ambulatory Surgery*, Vol 7, Suppl 1, S 56; April 1999.

COMUNICAZIONI a CONGRESSI

Maurichi A. Indications for Completion Lymph Node Dissection in melanoma patients with positive sentinel nodes: a monoinstitutional experience. Third International Educational Symposium of the Melanoma World Society. Cape Town, South Africa, March 01-03 2019

Maurichi A. Risk stratification of Sentinel Node Positive Melanoma Patients May Define Indications for Completion Lymph Node Dissection. International Sentinel Node Society Biennial Meeting. Tokyo, October 11-13, 2018

Maurichi A. Melanoma: Prevention and Screening. Lecture at the European Commition, Joint Research Centre, Ispra, June 08, 2018

Maurichi A. La Chirurgia del Melanoma: cambiamenti in arrivo? Lo stato dell'arte. Nuovi orientamenti nella terapia del melanoma. Università di Perugia, Perugia, 12 Maggio, 2018

Maurichi A. Melanocytic tumors of uncertain biologic potential: what are they and how to manage? Hot Topics In Melanoma & Non-Melanoma. Skin Cancer 2018 Florence, April 12-14, 2018

Maurichi A. Merkel cell carcinoma: new insights in surgical and systemic treatment. Hot Topics In Melanoma & Non-Melanoma. Skin Cancer 2018 Florence, April 12 14, 2018

Maurichi A. Trattamenti locoregionali ed immunoterapia [XXIII Congresso Nazionale I.M.I. - Intergruppo Melanoma Italiano](#). Milano 5-7 Novembre 2017

Maurichi A. Rationale use of sentinel node biopsy in thin melanomas. European Society of Surgical Oncology (ESSO) advanced course on the surgical and medical management of melanoma. focus on stage III and IV melanoma. In partnership with the Society of Surgical Oncology (SSO). Athens 9-11 November 2017.

Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Lamera M. Prendersi cura del paziente con melanoma. L'importanza dell'approccio multidisciplinare. Università di Brescia, 29 Maggio, 2017

Maurichi A, Patuzzo R, Gallino G, Ruggeri R, Mattavelli I, Tolomio E, Moglia D, Girgenti V, Santinami M. Metastastomies. Select the right patients. 2nd Advanced Course on the Surgical and Medical Management of Melanoma. European Society of Surgical Oncology, Athens, November 12-14, 2015

Maurichi A, Patuzzo R, Gallino G, Ruggeri R, Mattavelli I, Tolomio E, Moglia D, Girgenti V, Bono A, Santinami M. Superficial and Deep Groin Dissection in SN Era. Satellite Symposium "Surgery Bridge", Melanoma Bridge, Napoli, December 1, 2015

Maurichi A. Nevi Cutanei. Lettura. 80° corso di aggiornamento Società Italiana Pediatria. La Pediatria nella Pratica Clinica. Milano, 12-14 Marzo 2015.

Maurichi A, Gallino G, Moglia D, Patuzzo R, Ruggeri R, Tolomio E, Girgenti V, Bono A, Di Florio A, Brunelli D, Castelli G, Santinami. The need for completion dissection in patients with sentinel node biopsy positive: experience at National Cancer Institute of Milan with 1143 cases. 1st Euro-Asian Melanoma Congress in Bosnia & Herzegovina. Sarajevo, 18 - 21 September 2014

Maurichi A, Gallino G, Moglia D, Patuzzo R, Ruggeri R, Tolomio E, Santinami M. Pathological and Clinical Staging of Melanoma. European Society of Surgical Oncology (ESSO) Advanced Course on the Surgical and Medical Management of Melanoma. Santorini, October 10-13, 2013

Maurichi A, Camerini T, Crippa F, Moglia D, Patuzzo R, Ruggeri R, Tolomio E, Santinami M. Thin Cutaneous Melanoma (≤ 1 mm). Determinants of Prognosis and Survival. Perspectives in Melanoma XV. New York, September 16-17, 2011

Mortarini R, Mella A, Vegetti C, Bersani I, Zappasodi R, Arienti F, Ravagnani F, **Maurichi A**, Patuzzo R, Santinami M, Di Nicola M, Anichini A. Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma. 52nd Annual Meeting of the Italian Cancer Society. Rome, October 4-7, 2010

Maurichi A, Patuzzo R, Bono A, Crippa F, Moglia D, Pellitteri C, Ruggeri R, Tragni G, Tolomio E, Carbone A, Santinami M. Cutaneous Melanoma in Radial Growth Phase. 7th World Congress on Melanoma. Wien, May 12-16, 2009

Santinami M, Carbone A, Crippa F, Cutolo G, **Maurichi A**, Ruggeri R, Tragni G and Patuzzo R. Radical dissection in presence of positive groin SNB in melanoma patients: overtreatment or adequate surgery? 60th Annual Cancer Symposium of the Society of Surgical Oncology. Washington D.C., March 15-18, 2007.

Rivoltini L, Pilla L, Filipazzi P, Casati C, Cutolo G, Sovena G, Tragni G, Patuzzo R, **Maurichi A**, Santinami M, Castelli C and Parmiani G. Multi-peptide vaccination in high risk stage II-III melanoma patients: are we boosting the right immune responses for preventing disease recurrence? Annual Congress Italian Melanoma Intergroup. Bari 30/11-02/12 2006

Maurichi A, Patuzzo R, Pennacchioli E, Liborio F, Tragni G, Baldi M, Bartoli C, Bono A, Moglia D, Santinami M. Cutaneous desmoplastic melanoma. Proceedings of the 6th World Congress on Melanoma. Vancouver, September 6-10, 2005.

Moglia D, Baldi M, Bartoli C, Bono A, Liborio F, **Maurichi A**, Patuzzo R, Pennacchioli E, Santoro N, Santinami M. Surgical treatment in horizontal growth phase melanoma. Results of a prospective study. Proceedings of the 6th World Congress on Melanoma. Vancouver, September 6-10, 2005.

Maurichi A, Bartoli C, Bono A, Liborio F, Moglia D, Patuzzo R, Pennacchioli E, Rebuffoni G, Santinami M, Garbagnati F. Radiofrequency thermal ablation of liver melanoma metastases. A study of 19 cases. Proceedings of the 6th World Congress on Melanoma. Vancouver, September 6-10, 2005.

Patuzzo R, Bartoli C, Bono A, Deraco M, Liborio F, **Maurichi A**, Moglia D, Roberto M, Santinami M, Pennacchioli E. Regional perfusion for limbs in transit metastases for melanoma: result in a single institution. Proceedings of the 6th World Congress on Melanoma. Vancouver, September 6-10, 2005.

Santinami M, Bartoli C, Bono A, Liborio F, **Maurichi A**, Moglia D, Roberto M, Tragni G, Pennacchioli E. Morphologic evaluation of the sentinel node does not correlate with survival of melanoma patients. Proceedings of the 6th World Congress on Melanoma.

Vancouver, September 6-10, 2005.

Santinami M, Bartoli C, Bono A, Costanzo P, **Maurichi A**, Moglia D, Patuzzo R, Santoro N, Tragni G, Pennacchioli E. Sentinel node biopsy: standard treatment for melanoma? Results at the National Cancer Institute of Milan. Proceedings of the 6th World Congress on Melanoma. Vancouver, September 6-10, 2005.

Pennacchioli E, Baldi M, Bartoli C, Bono A, **Maurichi A**, Moglia D, Patuzzo R, Ruggeri R, Tragni G, Santinami M. Radical dissection of groin basin after positive SNB: overtreatment or standard surgery? Proceedings of the 6th World Congress on Melanoma. Vancouver, September 6-10, 2005.

Pennacchioli E, Baldi M, Bartoli C, Bono A, **Maurichi A**, Moglia D, Patuzzo R, Ruggeri R, Santinami M. Frequency and management of non sentinel node metastases in the groin basin of melanoma patients. Proceedings of the 10th World Congress on Cancer of the Skin. Wien, May 13-16, 2005. FC13, p9

Santinami M, Baldi M, Bartoli C, Bono A, **Maurichi A**, Moglia D, Patuzzo R, Pennacchioli E, Cascinelli N. Extent of lymphadenectomy. *Medicina Cutanea* vol. 31, Suppl 1. Mayo-Junio 2003.

Pennacchioli E, Santinami M, Baldi M, Bartoli C, Bono A, Clemente C, **Maurichi A**, Moglia D, Patuzzo R, Cascinelli N. Sentinel node biopsy: staging or therapeutic tool? *Medicina Cutanea* vol. 31, Suppl 1, Mayo-Junio 2003.

Santinami M, Bono A, Baldi M, Bartoli C, Moglia D, Santoro N, **Maurichi A**, Patuzzo R, Pennacchioli E, Cascinelli N. More limited surgical margins may suffice in invasive horizontal phase melanoma. 1st Mediterranean Melanoma Meeting. Mediterranean Sea-Aegean, 2-5 May 2003. Abstr 013

Moglia D, Baldi M, Bartoli C, Bono A, **Maurichi A**, Patuzzo R, Santoro N, Santinami M. Intervento in regime ambulatoriale o di day-surgery in dermatologia oncologica: Una proposta per evitare il contenzioso con l'organo di controllo. VIII Congresso Nazionale Società Italiana di Chirurgia Ambulatoriale e di Day-Surgery (SICADS). Isola d'Elba, 11-14 maggio 2003.

Santinami M, Baldi M, Bartoli C, Bono A, **Maurichi A**, Moglia D, Patuzzo R, Pennacchioli E, Cascinelli N. Indicazioni e limiti dello studio per immagini. Atti XVII Congresso Nazionale Società Italiana Chirurgia Oncologica. Cagliari 29-31 Maggio 2003.

Cascinelli N, Baldi M, Bartoli C, Bifulco C, Bono A, Clemente C, **Maurichi A**, Moglia D, Patuzzo R, Pennacchioli E, Santinami M. Role of sentinel node biopsy. Pro-ceedings of the Twelfth International Congress on Anti-Cancer Treatment. Paris, February 4 - 7th, 2002.

Cascinelli N, Baldi M, Bartoli C, Bono A, **Maurichi A**, Moglia D, Patuzzo R, Pennacchioli E, Santinami M. The role of alpha-interferon in the adjuvant setting for high-risk melanoma: a critical overview. Proceedings of the Twelfth International Congress on Anti-Cancer Treatment. Paris, February 4 -7th, 2002.

Santinami M, Baldi M, Bartoli C, Bono A, Clemente C, **Maurichi A**, Moglia D, Pennacchioli E, Patuzzo R, Cascinelli N. Le linfadenopatie: attualità e prospettive. ADOI, XL Congresso Nazionale, Sassari, 22-28 settembre 2002.

Bono A, **Maurichi A**, Moglia D, Tragni G, Camerini T, Bartoli C. Clinical diagnosis of amelanotic melanoma. Proceedings of the Fifth International Conference on Melanoma. Venice (Italy) 28 February-3 March, 2001.

Anichini A, **Maurichi A**, Bartoli C, Bono A, Molla A, Vegetti C, Sensi M, Mortarini R. Frequency and Phenotype of Melanocyte Lineage - Specific T Cells in melanoma patients is Tumor progression- and antigen- dependent. Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research. Vol 42, March 2001.

Bartoli C, Bono A, Moglia D, **Maurichi A**, Del Prato I, Camerini T, Tragni G, Lualdi M. Diagnosi precoce del melanoma acromico. Atti XV Congresso Nazionale Società Italiana Chirurgia

Oncologica (SIDCO). Trieste, 18-20 maggio 2000. Abstr. 33.

Moglia D, Bono A, Bartoli C, Del Prato I, **Maurichi A**, Majno E. Intervento in regime ambulatoriale o day-surgery in dermatologia oncologica: come evitare il contenzioso con l'organo di controllo. Atti XV Congresso Nazionale Società Italiana Chirurgia Oncologica. Trieste 18-20 maggio 2000. Abstr. 26.

Bartoli C, Bono A, Moglia D, **Maurichi A**. Terapia chirurgica dell'early melanoma. Atti XII Congresso Nazionale Società Italiana Dermatologia Chirurgica e Oncologica (SIDCO). Abano Terme 8-10 Maggio 1997. Abstr. 15R, p. 59.

Moglia D, **Maurichi A**, Tragni G, Bono A, Bartoli C. Il nevo di Reed: un simulatore smascherato. Atti XII Congresso Nazionale Società Italiana Dermatologia Chirurgica e Oncologica (SIDCO). Abano Terme 8-10 Maggio 1997. Abstr. 13C, p. 59.

PARTECIPAZIONI a TRIAL CLINICI

Philogen PROTOCOL PH-L19IL2TNF-02/15. A pivotal Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients.

Merck protocol MK-3475-054-01. Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group

Prot COMBI-AD: A Phase III randomized double blind study of dabrafenib (GSK2118436) in COMBination with trametinib (GSK1120212) versus two placebos in the Adjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection.

Prot. Eudra CT No 2010-019356-50 A Phase II Study of the Combination of Ipilimumab and Fostamustine in Patients with Unresectable Locally Advanced or Metastatic Malignant Melanoma Protocol Number: NIBIT-M1 (v. 1) February 1, 2010

Prot. Eudra CT No 2010-020663-20. An open Phase I Study of immunization with the recNY-ESO-1 + AS15 Antigen-Specific Cancer Immunotherapeutic in patients with NY-ESO-1-positive unresectable and progressive metastatic cutaneous melanoma. NYESO1-AS15-MEL-001 (MET)

Prot. Eudra CT No. 2009-016636-13 Phase I/II A Multicenter Phase I / II, open, to evaluate the safety, immunogenicity clinical activity of escalating doses of 'antigen-specific anti-cancer agent recPRAME + AS15 administered as first-line treatment in patients with metastatic melanoma, PRAME positive. 113173; PRAME-AS15-MEL-001 (MET) / n. INT 25/10

Prot. Eudra CT No. 2008-001194-14 *Phase 1* dose-finding study of tumor-targeting human monoclonal antibody-cytokine fusion protein L19TNF α plus melphalan using isolated inferior limb perfusion in patients with in-transit stage III/IV melanoma.

A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma. Prot No. 111482 "DERMA" (MAGE3-AS15 MEL-005). Cod EudraCT 2008-002447-16

Vaccination of high risk stage IIB-C/III melanoma patients with multipeptides, CpG ODN in Montanide and IL-2 versus Cpg-ODN alone. (P.I Prof. G. Parmiani, Dr. M. Santinami - INT Milano).

A phase I/II trial of active specific immunotherapy in patients with metastatic melanoma using

autologous tumor - derived heat shock protein-peptide complex-96 (HSPPC-96) vaccine. (P.I Prof. G. Parmiani - INT Milano).

Phase I/II trial evaluation of the effect of Interferon- α as adjuvant in the vaccination of patients affected by Phase IV Melanoma with MART-1:26-35 (27L) e gp100:209-217(210M) Peptides. (P.I. Prof. G. Parmiani, Dr. L. Rivoltini - INT Milano).

Open label, non randomized phase II study of Heat Shock Protein - Peptide Complex (HSPPC-96) in combination with GM - CSF and IFN- α in subjects with stage IV resectable malignant melanoma. (P.I. Prof. G. Parmiani - INT Milano).

A phase I-II study of active vaccination with autologous T -lymphocytes transduced with HSV - TK and MAGE - A3 in patients with metastatic melanoma and expression of MAGE A3. (P.I. Prof. G. Parmiani - INT Milano).

Protocol EORTC 18961: Post-Operative adjuvant ganglioside GM-KLH / QS-21 vaccination treatment after resection vs observation of primary cutaneous melanoma (AJCC Stage II, T3-T4N0M0)-A 2-arm multicenter randomized phase III trial. (P.I. Dr. M. Santinami - INT Milano).

A phase III randomized double - blind trial of immunotherapy with a polyvalent melanoma vaccine, *CancerVaxtm* vaccine plus BCG versus placebo plus BCG as a post - surgical treatment for stage IV melanoma (CV - MMAIT - 4 - 001). (P.I. Dr. M. Santinami - INT Milano).

Protocol EORTC 18991: PEG-Intron versus observation after regional lymph node dissection in AJCC stage III (TxN1-2M0) melanoma patients: a randomized phase III trial. (P.I. Dr. M. Santinami - INT Milano).

Vaccination of high risk stage IIB - C/III melanoma patients with multi-peptides, emulsified in Montanide and IL - 2 versus observation alone. (P.I. Dr. Santinami, Prof. G. Parmiani - INT Milano).

Genomic Research Project: Chromosomal localization of putative loci related to complex (polygenic) hereditary susceptibility to Melanoma (P.I. Dr. T.A. Dragani - INT Milano).

Research Project: Enrollment of spinocellular carcinoma patients family member to evaluate putative factor for hereditary susceptibility (P.I. Dr. T. A. Dragani - INT Milano).

Research Project: New Strategies in Melanoma Genetic Screening. Project sponsored by the Italian Health Institute (P.I. Dr. T.A. Dragani - INT Milano).

Research Project: Analysis of T-Cell Immune Response in patients affected by Primary Melanoma. (P.I. Dr. A. Anichini - INT Milano).

Pilot trial of a vaccination protocol with peptides derived from tumoral antigens, GM - CSF and KLH in Melanoma Phase IV patient: (P.I. Dr. L.Rivoltini, Prof. G. Parmiani - INT Milano).

A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma. (P.I. Dr. M. Santinami) - INT Milano

Studio di fase I/II, in aperto per valutare la sicurezza, l'immunogenicità e l'attività clinica di dose crescenti dell'agente immunoterapico antitumorale antigene-specifico rec-PRAME + AS15 somministrato come trattamento di prima linea in pazienti con melanoma metastatico, PRAME positivo prot. (P.I. Dr. M. Santinami) - INT Milano

Studio di fase II a braccio unico di combinazione con Ipilimumab e fotemustina in pazienti con melanoma in stadio III non resecabile o IV. - INT Milano

Tracing the melanoma lineage: cancer stem cells and genetic noise (P.I. Dr. M. Santinami, Dr. C. Laporta) INT Milano

Studio di fase I, in aperto, di immunizzazione con l'agente immunoterapico antitumorale antigene specifico rec-NY-ESO-1 + AS15, in pazienti con melanoma cutaneo metastatico NY-ESO-1 positivo inoperabile e in progressione. (P.I. Dr. M. Santinami) - INT Milano

Phase 1 dose-finding study of tumor-targeting human monoclonal antibody-cytokine fusion protein L19TNF α plus melphalan using isolated inferior limb perfusion in patients with in-transit stage III/IV melanoma (P.I. Dr. M. Santinami) INT Milano

A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients either in

clinical stage III or stage IV M1a with presence of injectable cutaneous and subcutaneous lesions. (P.I. Dr. M. Santinami) - INT Milano

Potiation of clinical and immunological effects of chemotherapy by neutralizing acidic pH at tumor site: a phase II randomized study in melanoma patients (P.I. Dr. M. Santinami) - INT Milano

A phase III randomized double blind study of dabrafenib (GSK2118436) in combination with trametinib (GSK1120212) versus placebo in the adjuvant treatment of high-risk BRAF V600 mutation-positive cutaneous melanoma after surgical resection (P.I. Dr. M. Santinami) INT Milano

Tracing the melanoma lineage: cancer stem cells and genetic noise (P.I. Dr. M. Santinami, Dr. C. Laporta) - INT Milano

A handwritten signature in black ink, appearing to read "Andrea Marchetti". The signature is written in a cursive, flowing style.

Milano, 30-06-2019